Recent advances in understanding of inflammatory bowel diseases (IBD) pathogenesis,
despite the questions remaining still unanswered, have led to improved approaches in …

Introduction: Inflammatory bowel disease (IBD) is an exceptional scenario with regard to
drug targeting, as oral administration has the potential to deliver the drug directly to the site …

In the last decade, substantial gains have been made in the treatment of inflammatory bowel
disease (IBD). Refinements in drug formulation have provided the ability to target distinct …

The immunological and genetic pathogeneses of inflammatory bowel disease (IBD) have
been well studied, but not well elucidated in recent years. Accordingly, the pharmacological …

Inflammatory bowel diseases (IBD) are idiopathic chronic inflammations: the etiology of
Crohn's disease (CD) and ulcerative colitis (UC) is still largely unknown. Environmental and …

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis
(UC), are chronic relapsing conditions resulting from immune system activity in a genetically …

Inflammatory bowel disease (IBD) is a term used to represent a group of chronic, relapsing
inflammatory disorders of the gastrointestinal tract. Crohn's disease (CD) and ulcerative …

Inflammatory bowel disease (IBD) refers to a gamut of disorders that are characterized by
chronic intestinal inflammation, including ulcerative colitis (UC) and Crohn's disease (CD) …

The etiology of inflammatory bowel disease (IBD) has not yet been clarified and
immunosuppressive agents which nonspecifically reduce inflammation and immunity have …

Inflammatory bowel disease (IBD) is a frequently occurring disease in young people, which
is characterized by chronic inflammation of the gastrointestinal tract. The therapy of IBD is …